for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neurobiological Technologies, Inc.

NTII.PK

Latest Trade

0.00USD

Change

0.00(0.00%)

Volume

700

Today's Range

0.00

 - 

0.00

52 Week Range

0.00

 - 

0.01

As of on the Over The Counter ∙ Minimum 15 minute delay

Pricing

Previous Close
0.00
Open
0.00
Volume
700
3M AVG Volume
0.08
Today's High
0.00
Today's Low
0.00
52 Week High
0.01
52 Week Low
0.00
Shares Out (MIL)
27.02
Market Cap (MIL)
0.05
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Neurobiological Technologies Inc Announces Dividend

Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share

Neurobiological Technologies Announces Stockholder Approval Of Plan Of Liquidation And Dissolution; Declares Extraordinary Dividend

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

Industry

Biotechnology & Drugs

Contact Info

2010 Crow Canyon Pl Ste 100

SAN RAMON, CA

94583-1344

United States

+1.925.3593247

Executive Leadership

Matthew M. Loar

Acting Chief Executive and Financial Officer, Director

William A Fletcher

Director

John B. Stuppin

Director

Key Stats

Price To Earnings (TTM)
0.00
Price To Sales (TTM)
0.00
Price To Book (MRQ)
0.04
Price To Cash Flow (TTM)
0.00
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
185.24
Return on Equity (TTM)
103.32

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up